The report “Bleeding Disorders Treatment Market by
Type Hemophilia A, Hemophilia B, vWD and others, by Drug Class – Plasma
Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor
Concentrates, Desmopressin, Antibrinolytics, Fibrin Sealant and Others –
Global Forecast to 2021″, report provides a detailed overview
of the major drivers, restraints, threats, opportunities, current market
trends, and strategies impacting the bleeding disorders treatment
market along with the estimates and forecasts of the revenue and market
share analysis.
Browse 36 market data Tables and 20 Figures spread through 170 Pages and in-depth TOC on “Bleeding
Disorders Treatment Market by Type Hemophilia A, Hemophilia B, vWD and
others, by Drug Class – Plasma Derived Coagulation Factor Concentrates,
Recombinant Coagulation Factor Concentrates, Desmopressin,
Antibrinolytics, Fibrin Sealant and Others – Global Forecast to 2021”.
Early buyers will receive 10% customization on reports.
This report studies the global bleeding disorders
treatment market over the forecast period of 2016 to 2021. This market
is valued at USD 10.33 Billion in 2016 and expected to grow at a CAGR of
7.9% from 2016 and 2021, to reach an estimated value of USD 15.09
Billion by 2021.
Download PDF Brochure: http://www.marketsandmarkets.com/pdfdownload.asp?id=71198026
The increasing prevalence of bleeding disorders and
their rising awareness are key market drivers. Government initiatives,
rising R&D activities, and investments by key players are further
expected to expedite the growth of bleeding disorders treatment market
globally.
The report segments this market based on type, drug
class, and region. The type segment is further classified into
hemophilia A, hemophilia B, von Willebrand Disease (vWD), and others.
The hemophilia A and B are further classified (based on disease
management) as prophylaxis and on-demand. The hemophilia A segment is
estimated to account for the largest share in 2015.
The drug class segment is further classified into
plasma-derived coagulation factor concentrates, recombinant coagulation
factor concentrates, desmopressin, antifibrinolytics, fibrin sealants,
and others. The recombinant coagulation factor concentrates segment is
estimated to account for the largest market share in 2015. Growth in
this market is attributed to the rising R&D investments for the
development and manufacturing of recombinant products by major players.
Plasma-derived segment is estimated to register the slowest CAGR, owing
to its reducing demand from end users due to risk of acquiring
blood-associated infections. Additionally, difficulty in sourcing plasma
from blood (due to scarcity of blood donors) further limits the growth
of plasma-derived coagulation factor concentrates market.
Based on region, the global bleeding disorders
treatment market is segmented into North America, Europe, Asia-Pacific
(APAC), and the Rest of the World (RoW). North America is estimated to
contribute the largest share of the market throughout the forecast
period. The market in APAC is estimated to register the highest CAGR
during the forecast period, owing to increasing awareness of these
disorders in the emerging economies such as India and China.
The key players operating in bleeding disorders
treatment market include Shire (U.S.), CSL Behring (U.S.), Bayer AG
(Germany), Novo Nordisk A/S (Denmark), Pfizer Inc. (U.S.), Biogen
(U.S.), and Octapharma (Switzerland).
Download Sample Report Pages: http://www.marketsandmarkets.com/requestsample.asp?id=71198026
About MarketsandMarkets™:
MarketsandMarkets™ provides quantified B2B research
on 30,000 high growth niche opportunities/threats which will impact 70%
to 80% of worldwide companies’ revenues. Currently servicing 5000
customers worldwide including 80% of global Fortune 1000 companies as
clients. Almost 75,000 top officers across eight industries worldwide
approach MarketsandMarkets™ for their painpoints around revenues
decisions.
Our 850 fulltime analyst and SMEs at
MarketsandMarkets™ are tracking global high growth markets following the
“Growth Engagement Model – GEM”. The GEM aims at proactive
collaboration with the clients to identify new opportunities, identify
most important customers, write “Attack, avoid and defend” strategies,
identify sources of incremental revenues for both the company and its
competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants
(Positioning top players across leaders, emerging companies, innovators,
strategic players) annually in high growth emerging segments.
MarketsandMarkets™ is determined to benefit more than 10,000 companies
this year for their revenue planning and help them take their
innovations/disruptions early to the market by providing them research
ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence
and market research platform, “RT” connects over 200,000 markets and
entire value chains for deeper understanding of the unmet insights along
with market sizing and forecasts of niche markets.
Contact:
Mr. Rohan
MarketsandMarkets™
701 Pike Street,
Suite 2175, Seattle,
WA 98101, United States
1-888-600-6441
Email: sales@marketsandmarkets.com
Mr. Rohan
MarketsandMarkets™
701 Pike Street,
Suite 2175, Seattle,
WA 98101, United States
1-888-600-6441
Email: sales@marketsandmarkets.com
Article Credit: Healthcare DC
Comments
Post a Comment